Toggle Offcanvas
...
 
Follitropin Tenders

Follitropin Tenders

View Follitropin tenders, RFPs and contracts. Bid on readily available Follitropin tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Follitropin tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Follitropin.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Follitropin market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Follitropin tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

42 Live Notices for Follitropin Tenders

Showing 1 to 20

Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So-Called Open House Procedure.
country Germany
posting date18 Nov 2024
deadline31 Dec 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So-Called Open House Procedure.
country Germany
posting date18 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Aug 2024
deadline03 Aug 2026
Pharmaceutical Discount Agreements For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Aug 2024
deadline03 Aug 2026
Open House Biologics Discount Agreements 2024-04 - Follitropin Alfa
country Germany
posting date22 Jun 2024
deadline31 Jul 2026
Open House Biologics Discount Agreements 2024-04 - Follitropin Alfa
country Germany
posting date22 Jun 2024
deadline31 Jul 2026
Open House Biologics Discount Agreements 2024-04 - Follitropin Alfa
country Germany
posting date21 Jun 2024
deadline31 Jul 2026
Open House Biologics Discount Agreements 2024-04 - Follitropin Alfa
country Germany
posting date21 Jun 2024
deadline31 Jul 2026
Open House Biologics Discount Agreements 2024-04 - Follitropin Alfa
country Germany
posting date21 Jun 2024
deadline31 Jul 2026
Open House Biologics Discount Agreements 2024-04 - Follitropin Alfa
country Germany
posting date21 Jun 2024
deadline31 Jul 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Follitropin Alfa (G03Ga05) As Part Of A So-Called Open House Model.
country Germany
posting date22 May 2024
deadline30 Apr 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Follitropin Alfa (G03Ga05) As Part Of A So-Called Open House Model.
country Germany
posting date22 May 2024
deadline30 Apr 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Follitropin Alfa (G03Ga05) Within The Framework Of A So-Called Open-House Model.
country Germany
posting date22 May 2024
deadline30 Apr 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Follitropin Alfa (G03Ga05) Within The Framework Of A So-Called Open-House Model.
country Germany
posting date22 May 2024
deadline30 Apr 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Follitropin Alfa (G03Ga05) As Part Of A So-Called Open House Model.
country Germany
posting date21 May 2024
deadline30 Apr 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Follitropin Alfa (G03Ga05) As Part Of A So-Called Open House Model.
country Germany
posting date21 May 2024
deadline30 Apr 2026
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Follitropin Alfa, Atc G03Ga05 For The Period February 1St, 2024 - January 31St, 2026
country Germany
posting date18 Dec 2023
deadline05 Dec 2025
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Follitropin Alfa, Atc G03Ga05 For The Period February 1St, 2024 - January 31St, 2026
country Germany
posting date18 Dec 2023
deadline05 Dec 2025

Share Share this page